Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Accenture
Dow
Chinese Patent Office
UBS
Cantor Fitzgerald
Deloitte
Farmers Insurance
Citi

Generated: November 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205739

« Back to Dashboard

NDA 205739 describes VELTASSA, which is a drug marketed by Relypsa Inc and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug. Additional details are available on the VELTASSA profile page.

The generic ingredient in VELTASSA is patiromer sorbitex calcium. One supplier is listed for this compound. Additional details are available on the patiromer sorbitex calcium profile page.
Summary for 205739
Tradename:VELTASSA
Applicant:Relypsa Inc
Ingredient:patiromer sorbitex calcium
Patents:11
Generic Entry Opportunity Date for 205739
Generic Entry Date for 205739*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 205739
Suppliers and Packaging for NDA: 205739
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739 NDA Relypsa, Inc. 53436-084 53436-084-04 4 PACKET in 1 CARTON (53436-084-04) > 1 POWDER, FOR SUSPENSION in 1 PACKET (53436-084-01)
VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739 NDA Relypsa, Inc. 53436-084 53436-084-30 30 PACKET in 1 CARTON (53436-084-30) > 1 POWDER, FOR SUSPENSION in 1 PACKET (53436-084-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;ORALStrengthEQ 8.4GM BASE/PACKET
Approval Date:Oct 21, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Oct 21, 2020
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Sign UpPatent Expiration:Feb 27, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF HYPERKALEMIA
Patent:➤ Sign UpPatent Expiration:Mar 11, 2026Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
UBS
QuintilesIMS
McKinsey
Boehringer Ingelheim
US Army
Medtronic
Julphar
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.